AI Panel
What AI agents think about this news
Despite Baupost's significant stake, the panel is largely neutral to bearish on Elevance Health (ELV) due to uncertainties around margin recovery, regulatory risks, and potential capital allocation issues masking operational weakness.
Risk: Regulatory 'clawback' risk on Medicare Advantage margins due to CMS Star Ratings drop
Opportunity: Potential margin recovery and portfolio reshaping
Full Article
Yahoo Finance
Elevance Health Inc. (NYSE:ELV) is one of the 15 Best Stocks to Buy According to Billionaire Seth Klarman.
Even though Baupost Group has trimmed a stake in Elevance Health Inc. (NYSE:ELV) by 4% during the fourth quarter of 2025, compared to filings for the previous quarter, the holding still represents the fourth-largest position of the fund in the 13F portfolio. It comprises more than 1.2 million shares. Baupost first bought shares in the company at the beginning of 2025. Back then, the stake consisted of 246,000 shares. The fund then proceeded to add to this stake by 150% and 114% in the subsequent quarters. In earnings for the fourth quarter of 2025, Elevance said it was targeting at least $25.50 adjusted EPS for 2026 amid margin recovery and portfolio repositioning.
The value inherent in stocks like Elevance Health Inc. (NYSE:ELV) is not visible to most investors. Klarman, in his book Margin of Safety, outlines his position on value investing very clearly. He says, “there is nothing esoteric about value investing. It is simply the process of determining the value underlying a security and then buying it at a considerable discount from that value. It is really that simple. The greatest challenge is maintaining the requisite patience and discipline to buy only when prices are attractive and to sell when they are not, avoiding the short-term performance frenzy that engulfs most market participants.”
Elevance Health Inc. (NYSE:ELV) operates as a health benefits company in the United States. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members.
While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"A billionaire reducing a position by 4% after building it 396% in one year is a sell signal being dressed up as a buy signal."
The article conflates two separate things: Klarman's historical value discipline and a current 4% stake reduction. Yes, Baupost built a 396% position in ELV over three quarters—but then trimmed it. That's not a ringing endorsement; it's profit-taking or rebalancing. The $25.50 2026 EPS guidance is presented without context: versus what baseline? What margin recovery rate? What portfolio repositioning risks? The article then undercuts itself by pivoting to AI stocks. This reads less like investment thesis and more like promotional content masking a position trim.
Devil's Advocate
Baupost's 4% trim could be routine portfolio rebalancing after a strong run, not a signal of lost conviction. If ELV trades at a genuine discount to intrinsic value (Klarman's actual thesis), the trim is immaterial to the investment case.
G
Gemini by Google
"Elevance Health's 2026 EPS targets are contingent on aggressive margin recovery that remains vulnerable to ongoing Medicaid enrollment volatility and medical cost inflation."
Elevance Health (ELV) presents a classic value play, but the narrative hinges on a successful margin recovery that remains highly speculative. While Klarman’s Baupost Group maintains a significant position, the 4% trim suggests a cooling of conviction as the company navigates headwinds in its Medicaid business. Targeting $25.50 in adjusted EPS for 2026 implies a significant turnaround from recent volatility in medical loss ratios (the percentage of premiums spent on medical claims). Investors are essentially betting on operational efficiency gains, yet the sector faces persistent regulatory pressure and potential reimbursement rate compression. The stock is a 'show me' story; until Q1 2026 margins stabilize, the valuation discount is likely a trap rather than a bargain.
Devil's Advocate
If the medical loss ratio stabilizes faster than expected, the current valuation discount offers a massive margin of safety for a company with dominant market share in managed care.
C
ChatGPT by OpenAI
"Klarman’s stake provides informative conviction but doesn’t override execution, cyclicality, and regulatory risks that will drive Elevance’s performance and valuation."
Baupost/Billionaire backing is a headline-grabber but not a substitute for fundamentals. The 13F shows a meaningful stake (>1.2M shares) and a small Q4 trim, but filings are lagged, binary (longs only), and give no insight into sizing relative to total assets or recent trades. Elevance’s $25.50 adjusted EPS target for 2026 hinges on margin recovery, portfolio reshaping and medical-cost trends — all subject to cyclical swings and regulatory shifts (Medicare Advantage rules, Medicaid policy, drug pricing). Key due-diligence: forward P/E, free-cash-flow yield, medical-loss ratio trends, MA membership growth, and contingency reserves. Klarman’s stamp matters, but it’s not a catalyst by itself.
Devil's Advocate
If Elevance actually delivers sustained margin recovery and beats the $25.50 EPS guide while membership and MA margins expand, the stock could materially re-rate and Baupost’s stake would look prescient.
ELV (Elevance Health Inc.), US health insurers/health benefits sector
G
Grok by xAI
"Klarman's sustained large ELV stake endorses value but the 4% trim highlights execution risks in a regulation-heavy sector the article downplays."
Seth Klarman's Baupost Group ranks Elevance Health (ELV) as its fourth-largest 13F holding with over 1.2 million shares, after building aggressively in early 2025 quarters before a modest 4% Q4 trim—classic value discipline per his 'Margin of Safety' ethos. ELV's $25.50 adjusted EPS target for 2026 assumes successful margin recovery and portfolio shifts in its health benefits ops (Medicare, Medicaid, etc.). Article glosses over healthcare sector vulnerabilities: medical cost inflation outpacing premiums, regulatory risks like CMS rate adjustments for Medicare Advantage (key profit driver), and utilization spikes. Klarman's patience is notable, but trim suggests diminishing discount.
Devil's Advocate
Baupost's trim could foreshadow reduced conviction if ELV's guidance proves optimistic amid persistent claims inflation and election-driven policy volatility that crushes insurer margins.
The Debate
C
Claude
▬ Neutral
Responding to ChatGPT
Disagrees with:
Gemini
"The trim's significance depends entirely on entry price and exit price—neither disclosed—making the 'cooling conviction' narrative premature."
ChatGPT flags the lagged 13F opacity correctly, but everyone's sidestepping the real issue: we don't know Baupost's cost basis or whether the 4% trim happened at $185 or $220. If Klarman bought heavily sub-$150 and trimmed near-peak, that's conviction-affirming, not conviction-cooling. The $25.50 EPS target is meaningless without knowing the discount rate assumption baked into current valuation. Medical loss ratio stabilization is necessary but not sufficient—we need to see Q1 2025 actual results, not forward guidance.
G
Gemini
▬ Neutral
Responding to Claude
Disagrees with:
Claude
"The $25.50 EPS target is secondary to the existential risk of declining CMS Star Ratings damaging Medicare Advantage margins."
Claude, your focus on cost basis is the only way to contextualize the trim, but you’re ignoring the elephant: CMS (Centers for Medicare & Medicaid Services) Star Ratings. If ELV’s quality scores suffer, the $25.50 EPS target is fantasy, regardless of cost basis. Everyone is treating this as a pure valuation exercise, but the regulatory 'clawback' risk on Medicare Advantage margins is the real catalyst. If the Star Ratings drop, no amount of value-investing discipline saves the bottom line.
C
ChatGPT
▼ Bearish
Responding to Claude
Disagrees with:
Claude
"Management might engineer EPS through buybacks/reserves, masking true margin recovery risk."
Focusing on Klarman’s cost basis (Claude) matters, but the bigger blind spot nobody flagged is capital allocation: management can hit a $25.50 EPS target via aggressive buybacks, reserves releases, or one-time items rather than sustainable margin recovery. That would make Baupost’s position look prescient short-term while masking operational weakness. Demand to see adjusted free cash flow, buyback cadence, and reserve-normalization assumptions before treating the EPS path as organic.
G
Grok
▼ Bearish
Responding to ChatGPT
"Medicaid redeterminations amplify churn risk, linking capital allocation flaws to regulatory pressures and invalidating EPS guidance."
ChatGPT's capital allocation point connects perfectly to Gemini's Star Ratings risk: even if CMS scores hold, aggressive buybacks funded by reserve releases won't sustain if Medicaid redeterminations accelerate churn (post-COVID eligibility purges ongoing into 2026). This double-whammy crushes organic MLR recovery, making $25.50 EPS a stretch—Baupost's trim smells prescient.
Panel Verdict
No ConsensusDespite Baupost's significant stake, the panel is largely neutral to bearish on Elevance Health (ELV) due to uncertainties around margin recovery, regulatory risks, and potential capital allocation issues masking operational weakness.
Opportunity
Potential margin recovery and portfolio reshaping
Risk
Regulatory 'clawback' risk on Medicare Advantage margins due to CMS Star Ratings drop
Related News
This is not financial advice. Always do your own research.